1. Agonist of the adenosine A3 receptor, IB-MECA, and inhibitor of cyclooxygenase-2, meloxicam, given alone or in a combination early after total body irradiation enhance survival of γ-irradiated mice
   Michal Hofer et al, 2014, Radiation and Environmental Biophysics CrossRef
2. Imaging Studies with A2A Receptor Antagonists
   Adriana Alexandre S. Tavares et al, 2015, The Adenosinergic System CrossRef
3. New insights in the pharmacotherapy of glaucoma
   Liliana Mititelu-Tarțău et al, 2019, Farmacist.ro CrossRef
4. Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma
   Jed Asher Lusthaus et al, 2016, Expert Opinion on Investigational Drugs CrossRef
5. Exciting directions in glaucoma
   Carol A. Rasmussen et al, 2014, Canadian Journal of Ophthalmology CrossRef
6. The Role of Endogenous Neuroprotective Mechanisms in the Prevention of Retinal Ganglion Cells Degeneration
   Marita Pietrucha-Dutczak et al, 2018, Frontiers in Neuroscience CrossRef
7. Ocular Purine Receptors as Drug Targets in the Eye
   Kenneth A. Jacobson et al, 2016, Journal of Ocular Pharmacology and Therapeutics CrossRef
8. Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects?
   Pier Andrea Borea et al, 2016, Trends in Pharmacological Sciences CrossRef
9. Structure-Activity Analysis of Biased Agonism at the Human Adenosine A3 Receptor
   Jo-Anne Baltos et al, 2016, Molecular Pharmacology CrossRef
10. Species dependence of A3 adenosine receptor pharmacology and function
    Zhan-Guo Gao et al, 2023, Purinergic Signalling CrossRef
11. Cordycepin induces apoptosis in SGC-7901 cells through mitochondrial extrinsic phosphorylation of PI3K/Akt by generating ROS
    Moussa Ide Nasser et al, 2017, International Journal of Oncology CrossRef
12. Do We Need to Study Metabolism and Distribution in the Eye: Why, When, and Are We There Yet?
    Upendra A. Argikar et al, 2017, Journal of Pharmaceutical Sciences CrossRef
13. Ocular Cubosome Drug Delivery System for Timolol Maleate: Preparation, Characterization, Cytotoxicity, Ex Vivo, and In Vivo Evaluation
    Jiayuan Huang et al, 2017, AAPS PharmSciTech CrossRef
14. Activation of adenosine A3 receptor protects retinal ganglion cells from degeneration induced by ocular hypertension
    Raquel Boia et al, 2020, Cell Death & Disease CrossRef
15. A3 Adenosine Receptor Ligands: From Discovery to Clinical Trials
    Kenneth A. Jacobson et al, 2023, Purinergic Receptors and their Modulators CrossRef
16. The A3Adenosine Receptor: History and Perspectives
    Pier Andrea Borea et al, 2015, Pharmacological Reviews CrossRef
17. Adenosine receptors as promising targets for the management of ocular diseases
    Eleonora Spinozzi et al, 2021, Medicinal Chemistry Research CrossRef
18. Design and Synthesis of 2,6-Disubstituted-4′-Selenoadenosine-5′-N,N-Dimethyluronamide Derivatives as Human A3 Adenosine Receptor Antagonists
    Hongseok Choi et al, 2021, Pharmaceuticals CrossRef
19. The expression of adenosine receptors changes throughout light induced retinal degeneration in the rat
    Manuel Soliño et al, 2018, Neuroscience Letters CrossRef
20. Combined pharmacological therapy of the acute radiation disease using a cyclooxygenase-2 inhibitor and an adenosine A3 receptor agonist
    Michal Hofer et al, 2014, Open Life Sciences CrossRef